Better Survival in Refractory CRC With Chemo Plus Bevacizumab, Real-World Study Says

By News Health
2 months Ago

(MedPage Today) — Overall survival (OS) in refractory metastatic colorectal cancer (mCRC) improved significantly with the addition of the VEGF inhibitor bevacizumab (Avastin) to chemotherapy, data from a real-world analysis showed.
A propensity…

Source link : https://www.medpagetoday.com/hematologyoncology/coloncancer/120069

Author :

Publish date : 2026-02-26 21:45:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

OA Trial Drug Seeks to Be Analgesic Alternative to NSAIDs

The Shah’s Spleen: What a Cold War Medical Crisis Reveals About American Justice

Docs Bite Back at Physician Health Program; PA's Med Spa Troubles; Doc Impostor

Cancer Moonshot Alum's Death From Colorectal Cancer Spotlights Young-Onset Disease

Building a Better Pre-Op Visit

FDA Analysis Says Infant Formula Supply Is Safe After Testing for Contaminants